What are the differences between dimercaptosuccinic acid (DMSA) and calcium‑diethylenetriamine‑pentaacetate (Ca‑DTPA) regarding indications, dosing, and use for chelation of heavy‑metal toxicity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

DMSA vs DTPA for Heavy Metal Chelation

DMSA is the preferred first-line chelating agent for lead, mercury, and arsenic poisoning due to its oral bioavailability, superior safety profile, and lower toxicity compared to other chelators, while Ca-DTPA is specifically indicated only for internal contamination with plutonium, americium, or curium.

Indications

DMSA (Dimercaptosuccinic Acid/Succimer)

  • Primary indication: Lead poisoning 1, 2, 3
  • Also effective for mercury and arsenic poisoning 1, 3
  • Used for moderate to severe lead toxicity with blood lead levels requiring chelation 2

Ca-DTPA (Calcium-Diethylenetriamine-Pentaacetate)

  • FDA-approved indication: Internal contamination with plutonium, americium, or curium ONLY 4
  • Not effective for: Uranium, neptunium, or radioactive iodine 4
  • May have utility in acute heavy metal poisoning with lead, cadmium, or mercury 5, though this is off-label

Key Pharmacologic Differences

Route of Administration

  • DMSA: Oral administration with ~5% GI absorption 4, making it practical for outpatient management
  • Ca-DTPA: Must be given intravenously or by inhalation; oral route ineffective 4

Distribution and Mechanism

  • DMSA: Distributed extracellularly, extensively metabolized to cysteine mixed disulfides (likely the active chelating moiety), with chelation occurring primarily in the kidney 2
  • Ca-DTPA: Rapidly distributed throughout extracellular fluid space, cleared by glomerular filtration unchanged, forms stable chelates by exchanging calcium for metals with greater binding capacity 4

Tissue Specificity for Lead

  • DMSA: More effective at reducing kidney lead concentrations 2
  • Ca-DTPA: More effective at mobilizing bone lead stores 2
  • Neither significantly penetrates the blood-brain barrier 2

Dosing

DMSA

  • Standard dose: 1050 mg/m²/day orally 6
  • Typically given in divided doses over 5-day courses with 10-day rest periods between courses 6
  • Multiple intermittent courses recommended for complete mobilization 1

Ca-DTPA

  • Critical dosing limitation: Only a single initial dose of Ca-DTPA is recommended 4
  • Standard dose: 1 gram IV or by inhalation 4
  • After initial dose, must switch to Zn-DTPA if continued chelation needed 4
  • If Zn-DTPA unavailable and Ca-DTPA continued, mandatory zinc supplementation required 4

Safety Profile and Toxicity

DMSA

  • Considerably lower toxicity than classic chelators like BAL 1
  • Less toxic than DMPS 1
  • Depletes zinc and copper, but to a lesser degree than Ca-DTPA 2
  • Transient hepatic transaminase elevation possible but rarely clinically significant 2
  • Rare severe mucocutaneous reactions requiring discontinuation 2

Ca-DTPA

  • Significant depletion of endogenous trace metals (zinc, magnesium, manganese) 4
  • Magnitude of depletion increases with split daily dosing, higher doses, and longer duration 4
  • Reduces serum alkaline phosphatase, LDH, and creatinine kinase activities 5
  • Deaths reported in patients with severe hemochromatosis receiving excessive doses 4
  • Caution required in hemochromatosis patients 4
  • Nebulized administration may exacerbate asthma 4
  • More potent for removing essential metals than Zn-DTPA 5

Clinical Efficacy Comparison

For Lead Poisoning

When comparing equimolar doses in adults:

  • Ca-DTPA more effective at lead mobilization (p = 0.04) 6
  • DMSA greater impact on reducing blood lead concentrations (p = 0.005) 6
  • Both significantly reduce clinical symptoms and are well-tolerated 6
  • However: Ca-DTPA's single-dose limitation and toxicity profile make DMSA the practical choice 4, 1

Timing Considerations

  • Both agents: Effectiveness decreases with time after contamination 4, 7
  • Chelation most effective within 24 hours of exposure 4
  • DMSA given orally after oral exposure efficiently removes metal from GI tract 7
  • Combined early treatment may be superior in some scenarios 7

Clinical Algorithm

For lead, mercury, or arsenic poisoning:

  1. Use DMSA as first-line agent 1, 2
  2. Administer orally in multiple courses with rest periods 6
  3. Monitor zinc and copper levels; supplement as needed 2

For plutonium, americium, or curium contamination:

  1. Give single dose of Ca-DTPA immediately 4
  2. Switch to Zn-DTPA for maintenance therapy 4
  3. Mandatory mineral supplementation if Ca-DTPA continued 4
  4. Avoid in severe hemochromatosis 4

Common Pitfall: Do NOT use multiple doses of Ca-DTPA without switching to Zn-DTPA or providing zinc supplementation—this causes severe trace metal depletion 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.